• 1
    Khare M, Keady D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother 2003; 4: 165177.
  • 2
    Apfalter P. MRSA/MRSE-VISA/GISA/VRSA-PRP-VRE: current gram positive problem bacteria and mechanism of resistance, prevalence and clinical consequences. Wien Med Wochenschr 2003; 153: 144147.
  • 3
    Evans RS, Lloyd JF, Abouzelof RH, Taylor CW, Anderson VR, Samore MH. System-wide surveillance for clinical encounters by patients previously identified with MRSA and VRE. Medinfo 2004; 11: 212216.
  • 4
    Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135136.
  • 5
    Anonymous. First US case of vancomycin resistant Staphylococcus aureus infection reported in a patient with chronic renal failure. Dial Transplant 2002; 31: 602603.
  • 6
    El Solh N, Davi M, Morvan A et al. Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides. J Antimicrob Chemother 2003; 52: 691694.
  • 7
    Bonora MG, Solbiati M, Stepan E et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 2006; 44: 11531155.
  • 8
    Burleson BS, Ritchie DJ, Micek ST, Dunne WM. Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy 2004; 24: 12251231.
  • 9
    Malbruny B, Canu A, Bozdogan B et al. Resistance to quinupristin–dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 22002207.
  • 10
    Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement, M100-S15. Wayne, PA: CLSI, 2005.
  • 11
    Chevalier P, Rey J, Pasquier O, Rouzier-Panis R, Harding N, Montay G. Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers. J Clin Pharmacol 2001; 41: 404414.
  • 12
    Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987; 31: 393397.
  • 13
    Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 11291140.
  • 14
    Wilson APR. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000; 39: 167183.
  • 15
    Michèa Hamzehpour M, Kahr A, Pechère JC. In vitro stepwise selection of resistance to quinolones, β-lactams and amikacin in nosocomial Gram-negative bacilli. Infection 1994; 22 (suppl 2): S105S110.
  • 16
    De Vecchi E, Nicola L, Zucchetti E, Drago L. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes. J Chemother 2006; 18: 379388.
  • 17
    Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007; 45: S129S136.
  • 18
    McCallum N, Karauzum H, Getzmann R et al. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob Agents Chemother 2006; 50: 23522360.
  • 19
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement, M100-S16. Wayne, PA: CLSI, 2006.
  • 20
    Cunha BA. Principles of antimicrobial formulary selection for P&T Committees. Part 2: Pharmacokinetics and pharmacodynamics. P&T 2003; 28: 468470.